Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

208
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
208
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

579
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
579
Angina IV: Management01:26

Angina IV: Management

230
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
230
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

211
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
211

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of Successful Implementation: A Mixed-Methods Evaluation of a Team-Based Telehealth Hypertension Management Program for Underserved Patients.

Journal of the American Heart Association·2026
Same author

Female community health volunteers' knowledge and confidence in providing community-based diabetes self-management support in Nepal: A biphasic mixed method evaluation.

PLOS global public health·2026
Same author

A Framework to Decipher and Report Implementation Strategies and Pragmatic Attributes of Trial Design Domains From Pre-Implementation Studies Identified From a Systematic Review: A Methodological Study.

Journal of evaluation in clinical practice·2026
Same author

Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).

Circulation·2024
Same author

Self-Measured Blood Pressure-Guided Pharmacotherapy: A Systematic Review and Meta-Analysis of United States-Based Telemedicine Trials.

Hypertension (Dallas, Tex. : 1979)·2024
Same author

Clinicians' self-reported efficacy in cardiovascular prevention practice in the southeastern United States.

Future cardiology·2023

Related Experiment Video

Updated: Jan 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Improvement and Implementation Science to Optimize Statin Therapy in Primary Prevention.

Sameer Acharya, Jillian Senner, Kanwal Ejaz

    Journal for Healthcare Quality : Official Publication of the National Association for Healthcare Quality
    |October 31, 2025
    PubMed
    Summary

    Implementing improvement and implementation science strategies significantly increased statin therapy optimization for primary prevention in eligible patients. This quality improvement program enhanced statin use in adults without atherosclerotic cardiovascular disease (ASCVD).

    Keywords:
    PDSAimplementation scienceprimary carequality improvementsix sigma

    More Related Videos

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
    08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    14.0K
    Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
    08:58

    Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

    Published on: March 11, 2017

    16.8K

    Related Experiment Videos

    Last Updated: Jan 12, 2026

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
    09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    15.0K
    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
    08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    14.0K
    Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
    08:58

    Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

    Published on: March 11, 2017

    16.8K

    Area of Science:

    • Quality Improvement
    • Implementation Science
    • Preventive Cardiology

    Background:

    • Statin therapy is underprescribed for primary prevention in the US, with less than 1/5th of eligible patients receiving it.
    • A gap exists in optimizing statin use for primary prevention among adults without atherosclerotic cardiovascular diseases (ASCVD).

    Purpose of the Study:

    • To enhance statin therapy optimization in primary prevention for eligible patients aged 40-75 without ASCVD.
    • To implement and evaluate a quality improvement program using contextually responsive implementation strategies.

    Main Methods:

    • A quality improvement program was conducted in a resident internal medicine clinic.
    • Plan-Do-Study-Act cycles and Lean Six Sigma principles were employed.
    • Needs assessments, barrier identification, and mapping of implementation strategies (IS) using the ERIC taxonomy were performed over two years.

    Main Results:

    • Significant improvements were observed in lipid panel orders (64.6% to 95.5%) and completion (78.6% to 95.3%).
    • ASCVD risk score completion increased dramatically from 3% to 91%.
    • Statin therapy optimization rose from 34.5% to 90% in the eligible patient cohort.

    Conclusions:

    • Improvement and implementation science approaches are effective for identifying needs and barriers to statin optimization.
    • Mapping implementation strategies to identified barriers can significantly improve statin use for primary prevention.
    • Reporting implementation strategies using the ERIC taxonomy aids in operationalizing these strategies in diverse settings.